Equities Analysts Offer Predictions for R1 RCM Inc.’s Q1 2024 Earnings (NASDAQ:RCM)

R1 RCM Inc. (NASDAQ:RCM) – Stock analysts at Leerink Partnrs decreased their Q1 2024 EPS estimates for shares of R1 RCM in a research report issued to clients and investors on Monday, April 29th. Leerink Partnrs analyst M. Cherny now expects that the healthcare provider will post earnings per share of $0.02 for the quarter, down from their previous forecast of $0.03. Leerink Partnrs has a “Outperform” rating on the stock. The consensus estimate for R1 RCM’s current full-year earnings is ($0.05) per share. Leerink Partnrs also issued estimates for R1 RCM’s Q4 2024 earnings at $0.05 EPS and FY2026 earnings at $0.42 EPS.

A number of other brokerages have also weighed in on RCM. Canaccord Genuity Group lowered their price objective on shares of R1 RCM from $17.00 to $16.00 and set a “buy” rating for the company in a report on Wednesday, March 20th. Truist Financial restated a “hold” rating and set a $16.00 price target on shares of R1 RCM in a research report on Monday, April 1st. Barclays reiterated an “equal weight” rating and issued a $14.00 price objective on shares of R1 RCM in a report on Wednesday, February 28th. KeyCorp restated a “sector weight” rating on shares of R1 RCM in a report on Wednesday, April 10th. Finally, SVB Leerink started coverage on R1 RCM in a research note on Monday, February 26th. They issued an “outperform” rating and a $14.00 price target on the stock. Five research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $16.87.

R1 RCM Trading Up 0.6 %

R1 RCM stock opened at $12.36 on Thursday. R1 RCM has a fifty-two week low of $8.87 and a fifty-two week high of $18.70. The firm’s fifty day moving average price is $12.89 and its 200-day moving average price is $11.41. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.83 and a current ratio of 1.83.

Hedge Funds Weigh In On R1 RCM

Institutional investors have recently bought and sold shares of the stock. Headlands Technologies LLC bought a new stake in R1 RCM during the 3rd quarter worth approximately $36,000. ANTIPODES PARTNERS Ltd raised its position in shares of R1 RCM by 429.5% during the 4th quarter. ANTIPODES PARTNERS Ltd now owns 5,623 shares of the healthcare provider’s stock valued at $59,000 after purchasing an additional 4,561 shares during the period. Salem Investment Counselors Inc. purchased a new position in shares of R1 RCM during the 4th quarter valued at $61,000. Van ECK Associates Corp boosted its holdings in R1 RCM by 20.5% in the 4th quarter. Van ECK Associates Corp now owns 6,141 shares of the healthcare provider’s stock worth $65,000 after buying an additional 1,044 shares during the period. Finally, Caas Capital Management LP purchased a new stake in R1 RCM in the 4th quarter worth $148,000. 61.10% of the stock is owned by institutional investors.

Insiders Place Their Bets

In related news, President John M. Sparby sold 10,046 shares of the company’s stock in a transaction on Thursday, March 7th. The stock was sold at an average price of $14.33, for a total transaction of $143,959.18. Following the completion of the sale, the president now owns 265,986 shares in the company, valued at $3,811,579.38. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 36.80% of the stock is currently owned by insiders.

About R1 RCM

R1 RCM Inc provides technology-driven solutions for the financial performance and patient experience of health systems, hospitals, and physician groups. It provides operating partnership/end-to-end solutions, which manages multiple aspects of the revenue cycle to realize financial leverage and revenue improvement for hospital and physician customers.